| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lenalidomide | FIMM | pan-cancer | AAC | -0.023 | 0.9 |
| mRNA | GNF-2 | GDSC1000 | pan-cancer | AAC | -0.0076 | 0.9 |
| mRNA | JW-74 | CTRPv2 | pan-cancer | AAC | -0.0065 | 0.9 |
| mRNA | CEP-701 | FIMM | pan-cancer | AAC | 0.017 | 0.9 |
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | 0.024 | 0.9 |
| mRNA | BRD-K09344309 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.9 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0049 | 0.9 |
| mRNA | CBB-1007 | CTRPv2 | pan-cancer | AAC | 0.007 | 0.9 |
| mRNA | MK-2206 | GDSC1000 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | SB-431542 | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |